This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human 4E-BP1 / EIF4EBP1 (rh 4E-BP1 / EIF4EBP1, NP_004086.1, Ser2- Ile118) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
Eukaryotic translation initiation factor 4E-binding protein 1, also known as Phosphorylated heat- and acid-stable protein regulated by insulin 1, 4E-BP1, eIF4E-binding protein 1 and EIF4EBP1, belongs to theeIF4E-binding protein family. EIF4EBP1 / 4E-BP1 regulates eIF4E activity by preventing its assembly into the eIF4F complex. It mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways. Nonphosphorylated EIF4EBP1 / 4E-BP1 competes with EIF4G1/EIF4G3 to interact with EIF4E. Insulin stimulated MAP-kinase (MAPK1 and MAPK3) or mTORC1 phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. It interacts with RPTOR as well. Endoplasmic reticulum (ER) stress-mediated apoptosis may play a crucial role in loss of pancreatic beta cell mass, contributing to the development of diabetes. Induction of EIF4EBP1 / 4E-BP1, the suppressor of the mRNA 5' cap-binding protein eukaryotic initiation factor 4E (eIF4E), is involved in beta cell survival under ER stress. EIF4EBP1 / 4E-BP1 induction contributes to the maintenance of beta cell homeostasis during ER stress and is a potential therapeutic target for diabetes.